Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirati Therapeutics (NQ: MRTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mirati Therapeutics < Previous 1 2 3 4 5 6 7 8 Next > Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards September 20, 2021 After data readout from KRAS drug adagrasib in colon cancer, Mirati Therapeutics Inc (NASDAQ: MRTX) has announced positive topline results from a Phase... Via Benzinga Exposures Product Safety Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO September 20, 2021 Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily... Via Benzinga The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight September 19, 2021 Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021 August 26, 2021 Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE: Via Benzinga Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation June 25, 2021 The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs June 25, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... Via Benzinga Exposures COVID-19 20 Stocks Moving in Friday's Pre-Market Session June 25, 2021 Gainers Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL) rose 83.4% to $16.34 in pre-market trading after the company reported a sharp rise in Q1 earnings and sales. Grove, Inc. (... Via Benzinga A Peek Into The Markets: US Stock Futures Up Following Thursday's Rally; Nike Posts Upbeat Results June 25, 2021 Pre-open movers U.S. stock futures traded higher in early pre-market trade. The Dow Jones surged more than 300 points, while the S&P 500 closed at a record high in the... Via Benzinga Topics Stocks Exposures US Equities 7 Stocks Moving In Thursday's After-Hours Session June 24, 2021 Gainers Mirati Therapeutics (NASDAQ: MRTX) shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for patients with... Via Benzinga Exposures Product Safety 14 Biotech Stocks To Watch Over The Next 6 Months June 23, 2021 Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... Via Benzinga Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor June 05, 2021 Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to... Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021 June 04, 2021 Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high... Via Benzinga The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing May 26, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... Via Benzinga QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) May 25, 2021 From QIAGEN N.V. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021 May 17, 2021 Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,... Via Benzinga 10 Biggest Price Target Changes For Monday May 17, 2021 Morgan Stanley boosted the price target on Applied Materials, Inc. (NASDAQ: AMAT) from $113 to $137. Applied Materials shares fell 1.1% to $123.46 in pre-market trading.... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021 May 10, 2021 Upgrades Barrington Research upgraded the previous rating for ViacomCBS Inc (NASDAQ:VIAC) from Market Perform to Outperform. For the first quarter, ViacomCBS had an EPS of... Via Benzinga 10 Biggest Price Target Changes For Monday May 10, 2021 BMO Capital boosted The Middleby Corporation (NASDAQ: MIDD) price target from $225 to $250. Middleby shares rose 1.9% to close at $182.83 on Friday. Atlantic Equities reduced... Via Benzinga The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight April 10, 2021 Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
